Physician profile

David C Wang

Physical Medicine & Rehabilitation · Mc Lean, VA

NPI 1144420894

$413.32

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$84.23

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pacira Therapeutics, INC. $122.10 2019
Bioventus LLC $97.67 2019-2022
Fidia Pharma USA INC. $70.53 2021-2022
Ardelyx, INC. $34.71 2024 Ibsrela
Pacira Pharmaceuticals Incorporated $27.14 2023 Iovera, Zilretta
Novartis Pharmaceuticals Corporation $23.30 2019
Novo Nordisk INC $22.38 2023 Wegovy
Theragen, INC. $15.49 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David C Wang

$413.32

in general payments reported 2019-2025

Years
2019-2024
Top company
Pacira Therapeutics, INC.

https://glasscript.com/doctor/96980/david-c-wang

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.